CUDC-907 showed intense activity to reduce the expression of crucial NHEJ and HR factors, including Rad51, Ku80, 53BP1, which provides the rationale to combine CUDC-907 with those DNA-damaging agents for the treatment of SCLC. The gene discussed is TP53BP1; the disease is small cell lung carcinoma.